Literature DB >> 24820142

Remission criteria and activity indices in psoriatic arthritis.

M L Acosta Felquer1, L Ferreyra Garrott, J Marin, E Catay, M Scolnik, V Scaglioni, S Ruta, J Rosa, E R Soriano.   

Abstract

Remission criteria and activity indices used in rheumatoid arthritis (RA) are often applied in psoriatic arthritis (PsA). Some new indices have been specifically developed for PsA. Our objective was to evaluate the performance of different remission criteria and activity indices in PsA. This is a cross-sectional study that includes consecutive patients with PsA. Information necessary to complete the following indices was captured: Composite Psoriatic Disease Activity Index (CPDAI), Psoriatic Arthritis Screening and Evaluation (PASE), Disease Activity Index for Psoriatic Arthritis (DAPSA), Disease Activity Score in 28 Joints (DAS28), Simplified Disease Activity Index (SDAI), Clinical Disease Activity Index (CDAI), and American College of Rheumatology and European League Against Rheumatism (ACR/EULAR) Boolean RA remission criteria. Patients were classified according to activity categories (remission, low, medium, or high disease activity). Correlation between indices was established. Fifty-five patients were included. Mean age was 53 years (SD = 12), and 35 (63.6 %) were males. Mean PsA disease duration was 5.9 years (SD = 8.5), and mean psoriasis duration was 15.9 (SD = 12.6). We found important differences in the percentage of patients classified as in remission by applying different remission criteria: DAS28 = 33 % (95 % confidence interval (CI) 20-45) vs ACR/EULAR = 4 % (95 % CI 1-17). Particularly, DAS28 and minimal disease activity seemed to be less stringent in PsA than the other indices. Of the specific PsA indices evaluated, CPDAI showed the poorest correlation with all the other activity measurements, although differences were not statistically significant in most cases. Disease activity in PsA is measured by many different indices. In spite they all showed good correlations between them, they classified different patients in different disease status.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24820142     DOI: 10.1007/s10067-014-2626-y

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  31 in total

1.  Validation and crosscultural adaptation of an argentine spanish version of the health assessment questionnaire disability index.

Authors:  Gustavo Citera; María S Arriola; José A Maldonado-Cocco; Marcos G Rosemffet; Mónica M Sánchez; Mario A Goñi; Alberto Spindler; Eleonora Lucero; Alberto Berman
Journal:  J Clin Rheumatol       Date:  2004-06       Impact factor: 3.517

Review 2.  The assessment of disease activity and outcomes in psoriatic arthritis.

Authors:  A Kavanaugh; S Cassell
Journal:  Clin Exp Rheumatol       Date:  2005 Sep-Oct       Impact factor: 4.473

3.  Criteria, frequency, and duration of clinical remission in psoriatic arthritis patients with peripheral involvement requiring second-line drugs.

Authors:  Fabrizio Cantini; Laura Niccoli; Carlotta Nannini; Emanuele Cassarà; Paolo Pasquetti; Ignazio Olivieri; Carlo Salvarani
Journal:  J Rheumatol Suppl       Date:  2009-08

Review 4.  Psoriatic arthritis assessment tools in clinical trials.

Authors:  P J Mease; C E Antoni; D D Gladman; W J Taylor
Journal:  Ann Rheum Dis       Date:  2005-03       Impact factor: 19.103

5.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice.

Authors:  J S Smolen; F C Breedveld; M H Schiff; J R Kalden; P Emery; G Eberl; P L van Riel; P Tugwell
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

6.  Validity, reliability, and sensitivity-to-change properties of the psoriatic arthritis screening and evaluation questionnaire.

Authors:  Patrick Lee Dominguez; M Elaine Husni; Elizabeth W Holt; Stephanie Tyler; Abrar A Qureshi
Journal:  Arch Dermatol Res       Date:  2009-07-15       Impact factor: 3.017

7.  Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs.

Authors:  F Cantini; L Niccoli; C Nannini; E Cassarà; P Pasquetti; I Olivieri; C Salvarani
Journal:  Rheumatology (Oxford)       Date:  2008-04-09       Impact factor: 7.580

8.  The PASE questionnaire: pilot-testing a psoriatic arthritis screening and evaluation tool.

Authors:  M Elaine Husni; Kathryn H Meyer; Darel S Cohen; Elinor Mody; Abrar A Qureshi
Journal:  J Am Acad Dermatol       Date:  2007-07-03       Impact factor: 11.527

Review 9.  Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11.

Authors:  Laura C Coates; Oliver FitzGerald; Philip J Mease; Dafna D Gladman; Vibeke Strand; Niti Goel; Ina Campbell; Gerald Krueger; Neil J McHugh; Philip S Helliwell
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

10.  The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis.

Authors:  Laura C Coates; Nuria Navarro-Coy; Sarah R Brown; Sarah Brown; Lucy McParland; Howard Collier; Emma Skinner; Jennifer Law; Anna Moverley; Sue Pavitt; Claire Hulme; Paul Emery; Philip G Conaghan; Philip S Helliwell
Journal:  BMC Musculoskelet Disord       Date:  2013-03-21       Impact factor: 2.362

View more
  8 in total

1.  Gender does not make a difference in "composite psoriatic disease activity index (CPDAI)" in patients with psoriatic arthritis.

Authors:  Gökçe Kenar; Handan Yarkan; Berrin Zengin; Gerçek Can; Merih Birlik; Fatoş Önen
Journal:  Rheumatol Int       Date:  2018-09-08       Impact factor: 2.631

Review 2.  Management of psoriatic arthritis in 2016: a comparison of EULAR and GRAPPA recommendations.

Authors:  Laure Gossec; Laura C Coates; Maarten de Wit; Arthur Kavanaugh; Sofia Ramiro; Philip J Mease; Christopher T Ritchlin; Désirée van der Heijde; Josef S Smolen
Journal:  Nat Rev Rheumatol       Date:  2016-11-10       Impact factor: 20.543

Review 3.  Measuring Outcomes in Psoriatic Arthritis.

Authors:  Alexis Ogdie; Laura C Coates; Philip Mease
Journal:  Arthritis Care Res (Hoboken)       Date:  2020-10       Impact factor: 4.794

Review 4.  An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy.

Authors:  María Laura Acosta-Felquer; Javier Rosa; Enrique R Soriano
Journal:  Open Access Rheumatol       Date:  2016-03-30

Review 5.  Ultrasound as a useful tool to integrate the clinical assessment of nail involvement in psoriatic arthritis.

Authors:  Jessica Gutierrez-Manjarrez; Marwin Gutierrez; Chiara Bertolazzi; Alfonso Afaro-Rodriguez; Carlos Pineda
Journal:  Reumatologia       Date:  2018-02-28

6.  Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona Registry.

Authors:  Philip J Mease; Carol J Etzel; William J Huster; Talia M Muram; April W Armstrong; Jeffrey R Lisse; Sabrina Rebello; Rhiannon Dodge; Mwangi James Murage; Jeffrey D Greenberg; William N Malatestinic
Journal:  RMD Open       Date:  2019-05-24

7.  Comparison of disease activity measures in early psoriatic arthritis in usual care.

Authors:  Kim Wervers; Jolanda J Luime; Ilja Tchetverikov; Andreas H Gerards; Marc R Kok; Cathelijne W Y Appels; Wiebo L van der Graaff; Johannes H L M van Groenendael; Lindy-Anne Korswagen; Josien J Veris-van Dieren; Johanna M W Hazes; Marijn Vis
Journal:  Rheumatology (Oxford)       Date:  2019-12-01       Impact factor: 7.580

8.  Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.

Authors:  Philip Helliwell; Laura C Coates; Oliver FitzGerald; Peter Nash; Enrique R Soriano; M Elaine Husni; Ming-Ann Hsu; Keith S Kanik; Thijs Hendrikx; Joseph Wu; Elizabeth Kudlacz
Journal:  Arthritis Res Ther       Date:  2018-10-29       Impact factor: 5.156

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.